Technical Analysis for OMED - OncoMed Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 0.79 5.05% 0.04
OMED closed up 5.05 percent on Friday, January 18, 2019, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical OMED trend table...

Date Alert Name Type % Chg
Jan 18 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Jan 18 Pocket Pivot Bullish Swing Setup 0.00%
Jan 18 Doji - Bearish? Reversal 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 17 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 5.05%
Jan 17 Wide Bands Range Expansion 5.05%
Jan 16 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.28%
Jan 16 Pocket Pivot Bullish Swing Setup 1.28%
Jan 16 Wide Bands Range Expansion 1.28%
Jan 16 Up 3 Days in a Row Strength 1.28%

Older signals for OMED ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

OncoMed Pharmaceuticals, Inc., a clinical development-stage biotechnology company, focuses on discovering and developing monoclonal antibody therapeutics targeting cancer stem Cells (CSCs). Its product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, as well as impact bulk tumor cells. The company's product candidates under development include Anti-DLL4 (demcizumab, OMP-21M18), a humanized monoclonal antibody that is in Phase Ib combination therapy trial for the treatment of patients with non-small-cell lung cancer and pancreatic cancer; Anti-DLL4/Anti-VEGF Bispecific, which has completed preclinical trail that targets and inhibits both DLL4 and vascular endothelial growth factor (VEGF); Anti-Notch2/3 (OMP-59R5) that is in single-agent Phase I safety and dose escalation trial for the treatment of solid tumor patients; Anti-Notch1 (OMP-52M51), which is in preclinical studies for the treatment of hematologic malignancies and solid tumors; and Anti-Fzd7 (OMP-18R5) that is in Phase I single-agent trial for the treatment of solid tumor patients. Its products also include Fzd8-Fc (OMP-54F28), a proprietary fusion protein based on a truncated form of the Frizzled8 receptor or Fzd8; and RSPO-LGR, a CSC pathway. OncoMed Pharmaceuticals, Inc. has a research and development agreement with GlaxoSmithKline LLC to develop therapeutic antibody product candidates targeting the Notch signaling pathway, such as anti-Notch2/3 (OMP-59R5) and anti-Notch1 (OMP-52M51); and a strategic alliance with Bayer Pharma AG to discover, develop, and commercialize anti-CSC biologic and small molecule therapeutics targeting the Wnt signaling pathway, including Anti-Fzd7 and Fzd8-Fc. The company was founded in 2004 and is headquartered in Redwood City, California.
Is OMED a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 3.62
52 Week Low 0.55
Average Volume 519,866
200-Day Moving Average 2.1628
50-Day Moving Average 1.0163
20-Day Moving Average 0.7174
10-Day Moving Average 0.7577
Average True Range 0.0959
ADX 22.15
+DI 17.9951
-DI 19.5579
Chandelier Exit (Long, 3 ATRs ) 0.5423
Chandelier Exit (Short, 3 ATRs ) 0.8377
Upper Bollinger Band 0.8503
Lower Bollinger Band 0.5845
Percent B (%b) 0.77
BandWidth 37.05046
MACD Line -0.064
MACD Signal Line -0.0978
MACD Histogram 0.0337
Fundamentals Value
Market Cap 29.73 Million
Num Shares 37.6 Million
EPS -2.36
Price-to-Earnings (P/E) Ratio -0.33
Price-to-Sales 5.43
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.88
Resistance 3 (R3) 0.88 0.86 0.87
Resistance 2 (R2) 0.86 0.83 0.86 0.86
Resistance 1 (R1) 0.82 0.82 0.82 0.82 0.85
Pivot Point 0.80 0.80 0.80 0.80 0.80
Support 1 (S1) 0.76 0.77 0.76 0.76 0.73
Support 2 (S2) 0.74 0.76 0.74 0.72
Support 3 (S3) 0.70 0.74 0.72
Support 4 (S4) 0.70